Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 1997

View Archived Issues

New antioxidants from Shiseido

Natural products for the treatment of BPH

MS&D reveals nonpeptide tachykinin antagonists

Metabotropic glutamate receptor modulators from Lilly

SmithKline Beecham focuses on hemoregulatory compounds

MMP and TNF production inhibitors described by DuPont Merck

Lilly reports new salt of PKC inhibitor with improved pharmaceutical properties

Mirapex now available in U.S.

Didronel PMO now available for expanded use in the U.K.

Losec available in U.K. for symptoms of dyspepsia

Dovonex cleared for use in children in the U.K.

Novel antitumor agents from Sanwa Kagaku

DuPont Merck investigates new approach to potent HIV protease inhibitors

Low-dose combination of ramipril and felodipine evaluated in SHR

JL-13 possesses atypical antipsychotic profile

ChiRex to purchase Glaxo Wellcome manufacturing site

Inositol for psychiatric disorders

Transcell and Merck & Co. collaborate on antibacterial research

Oxford GlycoSciences licenses compound for treatment of glycolipid storage disorders

Transdermal xanomeline in development for Alzheimer's disease

MGI Pharma launches INFeD for anemia in cancer patients

Immunex receives approval to market paclitaxel in Canada

NKH-477 possesses antidepressant effects

Perospirone vs. mosapramine for schizophrenia

Update on Pfizer/Ligand treatments for osteoporosis and breast cancer

Promising preliminary results from open trial of lamotrigine in depression

Jenner Technologies reports results from phase I/II trial of prostate cancer vaccine

ABS and Chinese Academy of Medical Science expand alliance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Flow Neuro wins FDA nod for at-home device for depression
BioWorld MedTech
Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...